Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Atossa Genetics Inc (ATOS)

NASDAQ
Symbol
Exchange
Currency
ATOSNASDAQUSD
ATOSBIVAMXN
Currency in USD
Disclaimer
1.4800
-0.0200(-1.33%)
Real-time Data

ATOS Comments

Great start to the week ahead of the Russell inclusion. Seeing all the volume at the beginning and end of the days the past week, it looks like buying has already started by the MMs and hedge funds. There is still passive index buying end of week, but don't expect any type of squeezes. All my June covered calls expired OTM since we closed under $6, and myu July covereds are between 7.5 and 9. I will either sell covered calls closer to end of week, and maybe buy puts to lock in profit if get over $10. Personally, I think around $8 is peak this week, but we'll see.
totally agree. I have $7.5 and 10s. I expect to buy them back real cheap as speculators leave ahead of Monday
ATOS up 2% $7.50 and $10 July calls down 10%
15%...any news about atos?
$ATOS Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
Looks like a lot of the pumpers have gone away for now. This is a Bio Pharm company. While I think there is potential for this to go up to $10 and $20 on a buyout, it can easily go under $2 again. Looking at option pricing, there is still a lot of IV. I was able to buy back all my sold calls under $6 for a small profit, and resell higher strikes. Unless you truly believe this will skyrocket over $10 in the next month, you should only be buying call spreads.
Guys I believe on the following, every position at the current prices should be considered cheap, my view is that a BO or partnership will be announced hence why I bought in the first place. I have other bio stocks like ADTX, Relief Therapeutics, Novavax, Gilead and I like to play with the potential.Bio stocks are risky and volatile but ATOS is a winner and my view is that their drug will be tested against other types of cancer too.I will post the following again for everyone which is interested and is “new” with ATOS: Cash in hand with no debt, inclusion and possible BO or partnership. For those thinking that 30-40$ price range is not possible I would like to remind them that Gilead offered 20B for a buyout recently for Trodelvy and I can consider this as a peak. 5B market cap or even 10B buyout offer is totally reasonable as if I remember Trodelvy covers about 10% of breast cancer types where ATOS drug covers about 62% if I am not mistaken. Holding since 0.91$ and I changed my sell order from 40$ to 80$ because FOMO should be considered.
Hopefully someone heeded my warning and sold their June or July before Wed. Today hurt, but selling covered calls lessened the ******** Next catalyst for price movement is June 25th for Russell 2000. I should be able to buy back my sold calls for cheap before then and sell again after.
Just got in this. Where is all the chatter on this?
why itis down with the positive news
buy rumorsell news
buy the rumor,sell the news
It's only phase 2 results, and good results were already expected. We ran up over 100% since end of May, and we're back to last week's price. Might be a little bumpy in the near term, but price shold stabilize by June 25th.
what is the news?
If you're still holding short term options, I'd recommend selling them and getting long dated ones or just stock. Likely IV crush after Wednesday.
you are Right..about options..bro...tomorrow is the news are good..we don't need options any more..1 year price will be above 100$ 2 or 4 280$$ I'm going for long term my retirement is in 5 years.GLTA
If you're just going to hold for years, why have you been pumping and shilling so much lately?
$ATOS "Buy on the rumor, sell on the news." It's a famous saying. "holding" may be the best strategy.
I'm not an expert on stocks but I am a pharmacist, and I do believe endoxifen is a very promising drug. I'm very hopeful for this one
What's your price target if the data is positive?
at least 100$
Stop spreading misinformation. I'm bullish on the stock, but upcoming data is phase 2. We're years away from FDA approval. With positive results, buyout is more likely in the $20+ range this year or next. There's a reason why there's no long term call options available above $9.
hold don't sell this it's the path to 280$$ in 2 . 3years ENDOXIFEN
RIP my covered calls
Hey joe what do you think will happen monday?
Extremely overbought (RSI114) and prediction at < $1 after a year.
Extremely overbought (RSI114) and prediction at < $1 after a year.
Lol we know who’s losing money as it goes up! The WSJ has a price target of $8 you chode. Apread your false info elsewhere
Needle D - Charts, Algorithm, RSI don't lie LOL
LOL How is ATOS doing, Needle D?
$ATOS
Today it goes into Russell 2000. June Will be a really good Month for ATOS. I see it around 8 USD
today 4.25, 4.30
hold 🚀🚀🚀🚀=280
What's the basis of your prediction?
Endoxifen is the future for Ovarian Cancer...
Stevie Wonderful!
3.20 now. in 2. 3 year 280$$
4 lets go
go to 4$
Pls come down
Why?
$4 until this Wednesday
i sold covered calls. It can moon later :(
..
...
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.